uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.778 | Q16 | What Small molecule therapies have been approved by the FDA to treat anus disease? | There are no drug Small molecule therapies approved to treat anus disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anus disease" OR LOWER(mesh_heading) = "anus disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1396 | Q16 | What Small molecule therapies have been approved by the FDA to treat oculocutaneous albinism? | There are no drug Small molecule therapies approved to treat oculocutaneous albinism. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oculocutaneous albinism" OR LOWER(mesh_heading) = "oculocutaneous albinism") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1252 | Q16 | What Small molecule therapies have been approved by the FDA to treat lichen disease? | There are no drug Small molecule therapies approved to treat lichen disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lichen disease" OR LOWER(mesh_heading) = "lichen disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1555 | Q16 | What Small molecule therapies have been approved by the FDA to treat pulpitis? | There are no drug Small molecule therapies approved to treat pulpitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pulpitis" OR LOWER(mesh_heading) = "pulpitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1745 | Q16 | What Small molecule therapies have been approved by the FDA to treat vascular malformation? | There are no drug Small molecule therapies approved to treat vascular malformation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vascular malformation" OR LOWER(mesh_heading) = "vascular malformation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.407 | Q16 | What Small molecule therapies have been approved by the FDA to treat Dengue Hemorrhagic Fever? | There are no drug Small molecule therapies approved to treat Dengue Hemorrhagic Fever. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dengue hemorrhagic fever" OR LOWER(mesh_heading) = "dengue hemorrhagic fever") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1524 | Q16 | What Small molecule therapies have been approved by the FDA to treat primary ciliary dyskinesia? | There are no drug Small molecule therapies approved to treat primary ciliary dyskinesia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary ciliary dyskinesia" OR LOWER(mesh_heading) = "primary ciliary dyskinesia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1534 | Q16 | What Small molecule therapies have been approved by the FDA to treat progressive supranuclear palsy? | There are no drug Small molecule therapies approved to treat progressive supranuclear palsy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "progressive supranuclear palsy" OR LOWER(mesh_heading) = "progressive supranuclear palsy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.105 | Q16 | What Protein therapies have been approved by the FDA to treat bone disease? | Vosoritide is the only Protein therapy approved by the FDA to treat bone disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bone disease" OR LOWER(mesh_heading) = "bone disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192660', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192663', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192666', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192669', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192672', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192675', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192678', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192681', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192684', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192687', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192690', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}, {'UUID': 'DrugTargetsIndication121923_text_1192693', 'drugName': 'Vosoritide', 'tradeNames_list': "['Voxzogo']", 'drugType': 'Protein', 'actionType': 'binding agent', 'target': 'ENSG00000159899', 'approvedSymbol': 'NPR2', 'approvedName': 'natriuretic peptide receptor 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.693 | Q16 | What Small molecule therapies have been approved by the FDA to treat acinar cell carcinoma? | There are no drug Small molecule therapies approved to treat acinar cell carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acinar cell carcinoma" OR LOWER(mesh_heading) = "acinar cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1286 | Q16 | What Small molecule therapies have been approved by the FDA to treat malignant hypertension? | There are no drug Small molecule therapies approved to treat malignant hypertension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malignant hypertension" OR LOWER(mesh_heading) = "malignant hypertension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.834 | Q16 | What Small molecule therapies have been approved by the FDA to treat bone sarcoma? | There are no drug Small molecule therapies approved to treat bone sarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bone sarcoma" OR LOWER(mesh_heading) = "bone sarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.63 | Q16 | What Protein therapies have been approved by the FDA to treat Sepsis? | Vasopressin is the only Protein therapy approved by the FDA to treat Sepsis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sepsis" OR LOWER(mesh_heading) = "sepsis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_692516', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692534', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692552', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692570', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692588', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692606', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692624', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692642', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692660', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692678', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692696', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692714', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692732', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692750', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692768', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692786', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692804', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692822', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692840', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692858', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692876', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692894', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692912', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692930', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692948', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692966', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_692984', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693002', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693020', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693038', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693056', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693074', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693092', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693110', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693128', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693146', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693164', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693182', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693200', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693218', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693236', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693254', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693272', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693290', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693308', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693326', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693344', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693362', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693380', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693398', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693416', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693434', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693452', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693470', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693488', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693506', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693524', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693542', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693560', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693578', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693596', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693614', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693632', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693650', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693668', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693686', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693704', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693722', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693740', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693758', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693776', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693794', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693812', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693830', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693848', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693866', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693884', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693902', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693920', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693938', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693956', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693974', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_693992', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694010', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694028', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694046', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694064', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694082', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694100', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694118', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694136', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694154', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694172', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694190', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694208', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694226', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694244', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694262', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694280', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}, {'UUID': 'DrugTargetsIndication121923_text_694298', 'drugName': 'Vasopressin', 'tradeNames_list': "['Beta-Hypophamine', 'Leiormone', 'Pitressin', 'Vasophysin', 'Vasostrict']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.860 | Q16 | What Small molecule therapies have been approved by the FDA to treat carcinoid heart disease? | There are no drug Small molecule therapies approved to treat carcinoid heart disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "carcinoid heart disease" OR LOWER(mesh_heading) = "carcinoid heart disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1186 | Q16 | What Small molecule therapies have been approved by the FDA to treat immunodeficiency disease? | Maraviroc is the only Small molecule therapy approved by the FDA to treat immunodeficiency disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "immunodeficiency disease" OR LOWER(mesh_heading) = "immunodeficiency disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938287', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938308', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938329', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938350', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938371', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938392', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938413', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938434', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938455', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938476', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938497', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938518', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938539', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938560', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}, {'UUID': 'DrugTargetsIndication121923_text_938581', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.225 | Q16 | What Protein therapies have been approved by the FDA to treat multiple system atrophy? | There are no drug Protein therapies approved to treat multiple system atrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "multiple system atrophy" OR LOWER(mesh_heading) = "multiple system atrophy") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.146 | Q16 | What Protein therapies have been approved by the FDA to treat diffuse large B-cell lymphoma? | There are no drug Protein therapies approved to treat diffuse large B-cell lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diffuse large b-cell lymphoma" OR LOWER(mesh_heading) = "diffuse large b-cell lymphoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.376 | Q16 | What Small molecule therapies have been approved by the FDA to treat Cachexia? | Megestrol Acetate is the only Small molecule therapy approved by the FDA to treat Cachexia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cachexia" OR LOWER(mesh_heading) = "cachexia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940512', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cachexia', 'efo_term': 'Cachexia'}, {'UUID': 'DrugTargetsIndication121923_text_940533', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cachexia', 'efo_term': 'Cachexia'}, {'UUID': 'DrugTargetsIndication121923_text_940554', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cachexia', 'efo_term': 'Cachexia'}, {'UUID': 'DrugTargetsIndication121923_text_940575', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cachexia', 'efo_term': 'Cachexia'}, {'UUID': 'DrugTargetsIndication121923_text_940596', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cachexia', 'efo_term': 'Cachexia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1246 | Q16 | What Small molecule therapies have been approved by the FDA to treat leiomyosarcoma? | There are no drug Small molecule therapies approved to treat leiomyosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "leiomyosarcoma" OR LOWER(mesh_heading) = "leiomyosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1607 | Q16 | What Small molecule therapies have been approved by the FDA to treat scoliosis? | There are no drug Small molecule therapies approved to treat scoliosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "scoliosis" OR LOWER(mesh_heading) = "scoliosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1312 | Q16 | What Small molecule therapies have been approved by the FDA to treat mesothelioma? | Pemetrexed is the only Small molecule therapy approved by the FDA to treat mesothelioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mesothelioma" OR LOWER(mesh_heading) = "mesothelioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_918478', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918480', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918481', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918541', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918543', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918544', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918604', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918606', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918607', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918667', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918669', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918670', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918730', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918732', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918733', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918793', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918795', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918796', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918856', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918858', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918859', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918919', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918921', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918922', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918982', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918984', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918985', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919045', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919047', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919048', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919108', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919110', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919111', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919171', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919173', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919174', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919234', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919236', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919237', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919297', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919299', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919300', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919360', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919362', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant pleural mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919363', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1412 | Q16 | What Small molecule therapies have been approved by the FDA to treat oropharyngeal carcinoma? | There are no drug Small molecule therapies approved to treat oropharyngeal carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oropharyngeal carcinoma" OR LOWER(mesh_heading) = "oropharyngeal carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1123 | Q16 | What Small molecule therapies have been approved by the FDA to treat head and neck malignant neoplasia? | There are no drug Small molecule therapies approved to treat head and neck malignant neoplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "head and neck malignant neoplasia" OR LOWER(mesh_heading) = "head and neck malignant neoplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.10 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat liver disease? | Givosiran Sodium is the only Oligonucleotide therapy approved by the FDA to treat liver disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "liver disease" OR LOWER(mesh_heading) = "liver disease") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100359', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100361', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100363', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100365', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100367', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100369', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100371', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100373', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100375', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100377', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100379', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100381', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}, {'UUID': 'DrugTargetsIndication121923_text_1100383', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000023330', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'liver disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.453 | Q16 | What Small molecule therapies have been approved by the FDA to treat Genetic disorder of sex development? | There are no drug Small molecule therapies approved to treat Genetic disorder of sex development. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "genetic disorder of sex development" OR LOWER(mesh_heading) = "genetic disorder of sex development") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.713 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute promyelocytic leukemia? | Tretinoin is the only Small molecule therapy approved by the FDA to treat acute promyelocytic leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute promyelocytic leukemia" OR LOWER(mesh_heading) = "acute promyelocytic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1053517', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1053558', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000172819', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1053599', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1053640', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000077092', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1053681', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1053722', 'drugName': 'Tretinoin', 'tradeNames_list': "['Acticin', 'Altreno', 'Atralin', 'Avita', 'Renova', 'Retin-a', 'Retin-a microRetin-a-micro', 'Tretin-X', 'Tretinoin', 'Vesanoid']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000131759', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.257 | Q16 | What Protein therapies have been approved by the FDA to treat pituitary-dependent Cushing's disease? | There are no drug Protein therapies approved to treat pituitary-dependent Cushing's disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pituitary-dependent cushing's disease" OR LOWER(mesh_heading) = "pituitary-dependent cushing's disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.890 | Q16 | What Small molecule therapies have been approved by the FDA to treat cervical intraepithelial neoplasia? | There are no drug Small molecule therapies approved to treat cervical intraepithelial neoplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cervical intraepithelial neoplasia" OR LOWER(mesh_heading) = "cervical intraepithelial neoplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.392 | Q16 | What Small molecule therapies have been approved by the FDA to treat Churg-Strauss syndrome? | There are no drug Small molecule therapies approved to treat Churg-Strauss syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "churg-strauss syndrome" OR LOWER(mesh_heading) = "churg-strauss syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.916 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic interstitial cystitis? | There are no drug Small molecule therapies approved to treat chronic interstitial cystitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic interstitial cystitis" OR LOWER(mesh_heading) = "chronic interstitial cystitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.932 | Q16 | What Small molecule therapies have been approved by the FDA to treat clear cell renal carcinoma? | There are 7 Small molecule therapy drugs that are approved to treat clear cell renal carcinoma which are as follows: Pazopanib Hydrochloride, Cabozantinib S-Malate, Sorafenib Tosylate, Axitinib, Everolimus, Temsirolimus, and Belzutifan. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "clear cell renal carcinoma" OR LOWER(mesh_heading) = "clear cell renal carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_667823', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667851', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667879', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667907', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667935', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667963', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667991', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668019', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668047', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668075', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668103', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668131', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668159', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668187', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668215', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668243', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668271', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182866', 'approvedSymbol': 'LCK', 'approvedName': 'LCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668299', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182866', 'approvedSymbol': 'LCK', 'approvedName': 'LCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668327', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182578', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668355', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182578', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668383', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113263', 'approvedSymbol': 'ITK', 'approvedName': 'IL2 inducible T cell kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_668411', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': "['Votrient']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113263', 'approvedSymbol': 'ITK', 'approvedName': 'IL2 inducible T cell kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669556', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669579', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669602', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669625', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669648', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669671', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669694', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669717', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669740', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669763', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669786', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669809', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669832', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669855', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669878', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669901', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669924', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669947', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669970', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_669993', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670016', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670039', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670062', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670085', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670108', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670131', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670154', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670177', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670200', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670223', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670246', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670269', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670292', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670315', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670338', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670361', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670384', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670407', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670430', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670453', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670476', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670499', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670522', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670545', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670568', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670591', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670614', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670637', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670660', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670683', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670706', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670729', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670752', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670775', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670798', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670821', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670844', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670867', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670890', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670913', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670936', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670959', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_670982', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671005', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671028', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671051', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671074', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671097', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671120', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671143', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671166', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671189', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671212', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671235', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671258', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671281', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671304', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_671327', 'drugName': 'Cabozantinib S-Malate', 'tradeNames_list': "['Cabometyx', 'Cometriq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105976', 'approvedSymbol': 'MET', 'approvedName': 'MET proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1505 | Q16 | What Small molecule therapies have been approved by the FDA to treat posterior uveitis? | There are 2 Small molecule therapy drugs that are approved to treat posterior uveitis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "posterior uveitis" OR LOWER(mesh_heading) = "posterior uveitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217671', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_217879', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_218087', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_218295', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_218503', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_218711', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_218919', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_219127', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_219335', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_219543', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_219751', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_219959', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_220167', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_220375', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_220583', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_220791', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_226368', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_226653', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_226938', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_227223', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_227508', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_227793', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_228078', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_228363', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_228648', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_228933', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_229218', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_229503', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_229788', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_230073', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_230358', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_230643', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_230928', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_231213', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_231498', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_231783', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_232068', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}, {'UUID': 'DrugTargetsIndication121923_text_232353', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uveitis, Posterior', 'efo_term': 'posterior uveitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1093 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastric adenocarcinoma? | There are no drug Small molecule therapies approved to treat gastric adenocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastric adenocarcinoma" OR LOWER(mesh_heading) = "gastric adenocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.464 | Q16 | What Small molecule therapies have been approved by the FDA to treat HELLP syndrome? | There are no drug Small molecule therapies approved to treat HELLP syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hellp syndrome" OR LOWER(mesh_heading) = "hellp syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1122 | Q16 | What Small molecule therapies have been approved by the FDA to treat head and neck carcinoma? | There are no drug Small molecule therapies approved to treat head and neck carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "head and neck carcinoma" OR LOWER(mesh_heading) = "head and neck carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.966 | Q16 | What Small molecule therapies have been approved by the FDA to treat cutaneous Leishmaniasis? | There are no drug Small molecule therapies approved to treat cutaneous Leishmaniasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cutaneous leishmaniasis" OR LOWER(mesh_heading) = "cutaneous leishmaniasis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.505 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hypoalbuminemia? | There are no drug Small molecule therapies approved to treat Hypoalbuminemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypoalbuminemia" OR LOWER(mesh_heading) = "hypoalbuminemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.745 | Q16 | What Small molecule therapies have been approved by the FDA to treat alveolar rhabdomyosarcoma? | There are no drug Small molecule therapies approved to treat alveolar rhabdomyosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alveolar rhabdomyosarcoma" OR LOWER(mesh_heading) = "alveolar rhabdomyosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1627 | Q16 | What Small molecule therapies have been approved by the FDA to treat sinusitis? | There are 3 Small molecule therapy drugs that are approved to treat sinusitis which are as follows: Epinephrine, Phenylephrine Hydrochloride, and Oxymetazoline Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sinusitis" OR LOWER(mesh_heading) = "sinusitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_360831', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_360884', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_360937', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_360990', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361043', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361096', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361149', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361202', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361255', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361308', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361361', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361414', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361467', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361520', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361573', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361626', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361679', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361732', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361785', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361838', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361891', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361944', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_361997', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362050', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362103', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362156', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362209', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362262', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362315', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362368', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362421', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362474', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362527', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362580', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362633', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362686', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362739', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362792', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362845', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362898', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_362951', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363004', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363057', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363110', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363163', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363216', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363269', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363322', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363375', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363428', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363481', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363534', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363587', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363640', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363693', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363746', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363799', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363852', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363905', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_363958', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364011', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364064', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364117', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364170', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364223', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364276', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364329', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364382', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364435', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364488', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364541', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364594', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364647', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364700', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364753', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364806', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364859', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364912', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_364965', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365018', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365071', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365124', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365177', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365230', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365283', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365336', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365389', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365442', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365495', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365548', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365601', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365654', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365707', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365760', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365813', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365866', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365919', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_365972', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_366025', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}, {'UUID': 'DrugTargetsIndication121923_text_366078', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sinusitis', 'efo_term': 'sinusitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.876 | Q16 | What Small molecule therapies have been approved by the FDA to treat celiac disease? | There are no drug Small molecule therapies approved to treat celiac disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "celiac disease" OR LOWER(mesh_heading) = "celiac disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.737 | Q16 | What Small molecule therapies have been approved by the FDA to treat allergic bronchopulmonary aspergillosis? | There are no drug Small molecule therapies approved to treat allergic bronchopulmonary aspergillosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "allergic bronchopulmonary aspergillosis" OR LOWER(mesh_heading) = "allergic bronchopulmonary aspergillosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.543 | Q16 | What Small molecule therapies have been approved by the FDA to treat Mastodynia? | There are no drug Small molecule therapies approved to treat Mastodynia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mastodynia" OR LOWER(mesh_heading) = "mastodynia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.702 | Q16 | What Small molecule therapies have been approved by the FDA to treat acute kidney failure? | There are no drug Small molecule therapies approved to treat acute kidney failure. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute kidney failure" OR LOWER(mesh_heading) = "acute kidney failure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1281 | Q16 | What Small molecule therapies have been approved by the FDA to treat male breast carcinoma? | There are no drug Small molecule therapies approved to treat male breast carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "male breast carcinoma" OR LOWER(mesh_heading) = "male breast carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1207 | Q16 | What Small molecule therapies have been approved by the FDA to treat interstitial lung disease? | There are no drug Small molecule therapies approved to treat interstitial lung disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "interstitial lung disease" OR LOWER(mesh_heading) = "interstitial lung disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1039 | Q16 | What Small molecule therapies have been approved by the FDA to treat esophageal cancer? | There are no drug Small molecule therapies approved to treat esophageal cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "esophageal cancer" OR LOWER(mesh_heading) = "esophageal cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.375 | Q16 | What Small molecule therapies have been approved by the FDA to treat COVID-19? | There are no drug Small molecule therapies approved to treat COVID-19. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "covid-19" OR LOWER(mesh_heading) = "covid-19") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.671 | Q16 | What Small molecule therapies have been approved by the FDA to treat Urethral stricture? | There are no drug Small molecule therapies approved to treat Urethral stricture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "urethral stricture" OR LOWER(mesh_heading) = "urethral stricture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1344 | Q16 | What Small molecule therapies have been approved by the FDA to treat muscular disease? | Duloxetine Hydrochloride is the only Small molecule therapy approved by the FDA to treat muscular disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "muscular disease" OR LOWER(mesh_heading) = "muscular disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205995', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206011', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206027', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206043', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206059', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206075', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206091', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206107', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206123', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206139', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206155', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206171', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206187', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206203', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206219', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206235', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206251', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206267', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206283', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206299', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206315', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206331', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206347', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206363', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206379', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206395', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206411', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206427', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206443', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206459', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206475', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}, {'UUID': 'DrugTargetsIndication121923_text_206491', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Musculoskeletal Pain', 'efo_term': 'muscular disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.360 | Q16 | What Small molecule therapies have been approved by the FDA to treat Bell's palsy? | There are no drug Small molecule therapies approved to treat Bell's palsy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bell's palsy" OR LOWER(mesh_heading) = "bell's palsy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.975 | Q16 | What Small molecule therapies have been approved by the FDA to treat dedifferentiated liposarcoma? | There are no drug Small molecule therapies approved to treat dedifferentiated liposarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dedifferentiated liposarcoma" OR LOWER(mesh_heading) = "dedifferentiated liposarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.791 | Q16 | What Small molecule therapies have been approved by the FDA to treat asthenia? | There are no drug Small molecule therapies approved to treat asthenia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "asthenia" OR LOWER(mesh_heading) = "asthenia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.741 | Q16 | What Small molecule therapies have been approved by the FDA to treat alopecia? | There are no drug Small molecule therapies approved to treat alopecia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alopecia" OR LOWER(mesh_heading) = "alopecia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1043 | Q16 | What Small molecule therapies have been approved by the FDA to treat essential hypertension? | There are no drug Small molecule therapies approved to treat essential hypertension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "essential hypertension" OR LOWER(mesh_heading) = "essential hypertension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.978 | Q16 | What Small molecule therapies have been approved by the FDA to treat depressive disorder? | There are 6 Small molecule therapy drugs that are approved to treat depressive disorder which are as follows: Trazodone Hydrochloride, Aripiprazole, Desvenlafaxine, Bupropion Hydrochloride, Lamotrigine, and Lorazepam. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "depressive disorder" OR LOWER(mesh_heading) = "depressive disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_155391', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155393', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155396', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155398', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155401', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155403', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155406', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155408', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155411', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155413', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155416', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155418', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155421', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155423', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155426', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155428', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155431', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155433', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155436', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155438', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155441', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155443', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155446', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155448', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155451', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155453', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155456', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155458', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155461', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155463', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155466', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155468', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155471', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155473', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155476', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155478', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155481', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155483', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155486', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155488', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155491', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155493', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155496', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155498', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155501', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155503', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155506', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_155508', 'drugName': 'Trazodone Hydrochloride', 'tradeNames_list': "['Desyrel', 'Molipaxin', 'Molipaxin cr', 'Oleptro', 'Trazodone hydrochlorideTrialodine']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159060', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159066', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159088', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159094', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159116', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159122', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159144', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159150', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159172', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159178', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159200', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159206', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159228', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159234', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159256', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159262', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159284', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159290', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159312', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159318', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159340', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159346', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159368', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159374', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159396', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159402', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159424', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159430', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159452', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159458', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159480', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159486', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159508', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159514', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159536', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159542', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159564', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159570', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159592', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159598', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159620', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159626', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159648', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159654', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159676', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159682', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159704', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159710', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159732', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159738', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}, {'UUID': 'DrugTargetsIndication121923_text_159760', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression'}, {'UUID': 'DrugTargetsIndication121923_text_159766', 'drugName': 'Aripiprazole', 'tradeNames_list': "['Abilify', 'Abilify maintena', 'Abilify maintena kit', 'Abilify mycite kitAripiprazole']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1343 | Q16 | What Small molecule therapies have been approved by the FDA to treat muscle cramp? | There are 6 Small molecule therapy drugs that are approved to treat muscle cramp which are as follows: Epinephrine, Lidocaine, Acetaminophen, Aspirin, Naproxen, and Ibuprofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "muscle cramp" OR LOWER(mesh_heading) = "muscle cramp") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_360833', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_360886', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_360939', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_360992', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361045', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361098', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361151', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361204', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361257', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361310', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361363', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361416', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361469', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361522', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361575', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361628', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361681', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361734', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361787', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361840', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361893', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361946', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_361999', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362052', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362105', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362158', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362211', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362264', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362317', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362370', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362423', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362476', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362529', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362582', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362635', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362688', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362741', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362794', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362847', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362900', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_362953', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363006', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363059', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363112', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363165', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363218', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363271', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363324', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363377', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363430', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363483', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363536', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363589', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363642', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363695', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363748', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363801', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363854', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363907', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_363960', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364013', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364066', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364119', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364172', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364225', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364278', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364331', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364384', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364437', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364490', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364543', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364596', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364649', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364702', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364755', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364808', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364861', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364914', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_364967', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365020', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365073', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365126', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365179', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365232', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365285', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365338', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365391', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365444', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365497', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365550', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365603', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365656', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365709', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365762', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365815', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365868', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365921', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_365974', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_366027', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}, {'UUID': 'DrugTargetsIndication121923_text_366080', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'muscle cramp'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1305 | Q16 | What Small molecule therapies have been approved by the FDA to treat meningeal tuberculosis? | There are 2 Small molecule therapy drugs that are approved to treat meningeal tuberculosis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "meningeal tuberculosis" OR LOWER(mesh_heading) = "meningeal tuberculosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217662', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_217870', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218078', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218286', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218494', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218702', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218910', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219118', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219326', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219534', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219742', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219950', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_220158', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_220366', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_220574', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_220782', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_226358', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_226643', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_226928', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_227213', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_227498', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_227783', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_228068', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_228353', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_228638', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_228923', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_229208', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_229493', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_229778', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_230063', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_230348', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_230633', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_230918', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_231203', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_231488', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_231773', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_232058', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_232343', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Meningeal', 'efo_term': 'meningeal tuberculosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1309 | Q16 | What Small molecule therapies have been approved by the FDA to treat mental or behavioural disorder? | There are no drug Small molecule therapies approved to treat mental or behavioural disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mental or behavioural disorder" OR LOWER(mesh_heading) = "mental or behavioural disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1750 | Q16 | What Small molecule therapies have been approved by the FDA to treat ventricular tachycardia? | Amiodarone Hydrochloride is the only Small molecule therapy approved by the FDA to treat ventricular tachycardia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ventricular tachycardia" OR LOWER(mesh_heading) = "ventricular tachycardia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_969560', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia'}, {'UUID': 'DrugTargetsIndication121923_text_969567', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia'}, {'UUID': 'DrugTargetsIndication121923_text_969574', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia'}, {'UUID': 'DrugTargetsIndication121923_text_969581', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia'}, {'UUID': 'DrugTargetsIndication121923_text_969588', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia'}, {'UUID': 'DrugTargetsIndication121923_text_969595', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tachycardia, Ventricular', 'efo_term': 'ventricular tachycardia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1515 | Q16 | What Small molecule therapies have been approved by the FDA to treat preeclampsia? | Spironolactone is the only Small molecule therapy approved by the FDA to treat preeclampsia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "preeclampsia" OR LOWER(mesh_heading) = "preeclampsia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094352', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}, {'UUID': 'DrugTargetsIndication121923_text_1094390', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}, {'UUID': 'DrugTargetsIndication121923_text_1094428', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}, {'UUID': 'DrugTargetsIndication121923_text_1094466', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}, {'UUID': 'DrugTargetsIndication121923_text_1094504', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}, {'UUID': 'DrugTargetsIndication121923_text_1094542', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}, {'UUID': 'DrugTargetsIndication121923_text_1094580', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}, {'UUID': 'DrugTargetsIndication121923_text_1094618', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}, {'UUID': 'DrugTargetsIndication121923_text_1094656', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toxemia', 'efo_term': 'preeclampsia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.893 | Q16 | What Small molecule therapies have been approved by the FDA to treat childhood absence epilepsy? | There are no drug Small molecule therapies approved to treat childhood absence epilepsy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "childhood absence epilepsy" OR LOWER(mesh_heading) = "childhood absence epilepsy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.80 | Q16 | What Protein therapies have been approved by the FDA to treat acute graft vs. host disease? | There are no drug Protein therapies approved to treat acute graft vs. host disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute graft vs. host disease" OR LOWER(mesh_heading) = "acute graft vs. host disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.822 | Q16 | What Small molecule therapies have been approved by the FDA to treat biliary tract neoplasm? | There are no drug Small molecule therapies approved to treat biliary tract neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "biliary tract neoplasm" OR LOWER(mesh_heading) = "biliary tract neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1499 | Q16 | What Small molecule therapies have been approved by the FDA to treat polyp? | There are no drug Small molecule therapies approved to treat polyp. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "polyp" OR LOWER(mesh_heading) = "polyp") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.675 | Q16 | What Small molecule therapies have been approved by the FDA to treat Ventricular arrhythmia? | There are 3 Small molecule therapy drugs that are approved to treat Ventricular arrhythmia which are as follows: Lidocaine, Sotalol Hydrochloride, and Amiodarone Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ventricular arrhythmia" OR LOWER(mesh_heading) = "ventricular arrhythmia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637779', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_637894', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638009', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638124', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638239', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638354', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638469', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638584', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638699', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638814', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_638929', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639044', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639159', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639274', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639389', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639504', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639619', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639734', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639849', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_639964', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640079', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640194', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640309', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640424', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640539', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640654', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640769', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640884', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_640999', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641114', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641229', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641344', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641459', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641574', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641689', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641804', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_641919', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642034', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642149', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642264', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642379', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642494', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642609', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642724', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642839', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_642954', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643069', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643184', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643299', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643414', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643529', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643644', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643759', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643874', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_643989', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644104', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644219', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644334', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644449', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_644564', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936145', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936148', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936151', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936154', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936157', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936160', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936163', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936166', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936169', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936172', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936175', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936178', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936181', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936184', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936187', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936190', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936193', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_936196', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_list': "['Beta-cardone', 'Betapace', 'Betapace af', 'Sorine', 'Sotacor', 'SotalexSotalol hydrochloride', 'Sotylize']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_969558', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_969565', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_969572', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_969579', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_969586', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}, {'UUID': 'DrugTargetsIndication121923_text_969593', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000055118', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arrhythmias, Cardiac', 'efo_term': 'Ventricular arrhythmia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1730 | Q16 | What Small molecule therapies have been approved by the FDA to treat urinary bladder carcinoma? | There are no drug Small molecule therapies approved to treat urinary bladder carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "urinary bladder carcinoma" OR LOWER(mesh_heading) = "urinary bladder carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.58 | Q16 | What Protein therapies have been approved by the FDA to treat Premature ovarian insufficiency? | There are no drug Protein therapies approved to treat Premature ovarian insufficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "premature ovarian insufficiency" OR LOWER(mesh_heading) = "premature ovarian insufficiency") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.134 | Q16 | What Protein therapies have been approved by the FDA to treat colorectal carcinoma? | There are no drug Protein therapies approved to treat colorectal carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colorectal carcinoma" OR LOWER(mesh_heading) = "colorectal carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.941 | Q16 | What Small molecule therapies have been approved by the FDA to treat colonic neoplasm? | There are no drug Small molecule therapies approved to treat colonic neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colonic neoplasm" OR LOWER(mesh_heading) = "colonic neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1487 | Q16 | What Small molecule therapies have been approved by the FDA to treat plexiform neurofibroma? | There are no drug Small molecule therapies approved to treat plexiform neurofibroma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "plexiform neurofibroma" OR LOWER(mesh_heading) = "plexiform neurofibroma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.831 | Q16 | What Small molecule therapies have been approved by the FDA to treat bone marrow failure syndrome? | There are no drug Small molecule therapies approved to treat bone marrow failure syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bone marrow failure syndrome" OR LOWER(mesh_heading) = "bone marrow failure syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.508 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hyponatremia? | Tolvaptan is the only Small molecule therapy approved by the FDA to treat Hyponatremia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyponatremia" OR LOWER(mesh_heading) = "hyponatremia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695093', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695108', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695123', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695138', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695153', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695168', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695183', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695198', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695213', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695228', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695243', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695258', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695273', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695288', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695303', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}, {'UUID': 'DrugTargetsIndication121923_text_695318', 'drugName': 'Tolvaptan', 'tradeNames_list': "['Jinarc', 'Jynarque', 'Samsca']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyponatremia', 'efo_term': 'Hyponatremia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1564 | Q16 | What Small molecule therapies have been approved by the FDA to treat reflex epilepsy? | There are no drug Small molecule therapies approved to treat reflex epilepsy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "reflex epilepsy" OR LOWER(mesh_heading) = "reflex epilepsy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.350 | Q16 | What Small molecule therapies have been approved by the FDA to treat Atrophic Vaginitis? | There are no drug Small molecule therapies approved to treat Atrophic Vaginitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "atrophic vaginitis" OR LOWER(mesh_heading) = "atrophic vaginitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.389 | Q16 | What Small molecule therapies have been approved by the FDA to treat Chorioretinitis? | There are 2 Small molecule therapy drugs that are approved to treat Chorioretinitis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chorioretinitis" OR LOWER(mesh_heading) = "chorioretinitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217626', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_217834', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_218042', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_218250', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_218458', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_218666', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_218874', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_219082', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_219290', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_219498', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_219706', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_219914', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_220122', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_220330', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_220538', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_220746', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_226318', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_226603', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_226888', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_227173', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_227458', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_227743', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_228028', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_228313', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_228598', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_228883', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_229168', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_229453', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_229738', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_230023', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_230308', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_230593', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_230878', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_231163', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_231448', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_231733', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_232018', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}, {'UUID': 'DrugTargetsIndication121923_text_232303', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1032 | Q16 | What Small molecule therapies have been approved by the FDA to treat epidermolysis bullosa? | There are no drug Small molecule therapies approved to treat epidermolysis bullosa. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "epidermolysis bullosa" OR LOWER(mesh_heading) = "epidermolysis bullosa") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.902 | Q16 | What Small molecule therapies have been approved by the FDA to treat chondrosarcoma? | There are no drug Small molecule therapies approved to treat chondrosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chondrosarcoma" OR LOWER(mesh_heading) = "chondrosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.836 | Q16 | What Small molecule therapies have been approved by the FDA to treat brain aneurysm? | There are no drug Small molecule therapies approved to treat brain aneurysm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "brain aneurysm" OR LOWER(mesh_heading) = "brain aneurysm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1663 | Q16 | What Small molecule therapies have been approved by the FDA to treat stricture? | There are no drug Small molecule therapies approved to treat stricture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "stricture" OR LOWER(mesh_heading) = "stricture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.479 | Q16 | What Small molecule therapies have been approved by the FDA to treat Henoch-Schoenlein purpura? | There are no drug Small molecule therapies approved to treat Henoch-Schoenlein purpura. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "henoch-schoenlein purpura" OR LOWER(mesh_heading) = "henoch-schoenlein purpura") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1291 | Q16 | What Small molecule therapies have been approved by the FDA to treat malignant tumor of neck? | There are no drug Small molecule therapies approved to treat malignant tumor of neck. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malignant tumor of neck" OR LOWER(mesh_heading) = "malignant tumor of neck") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1225 | Q16 | What Small molecule therapies have been approved by the FDA to treat islet cell tumor? | There are no drug Small molecule therapies approved to treat islet cell tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "islet cell tumor" OR LOWER(mesh_heading) = "islet cell tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.656 | Q16 | What Small molecule therapies have been approved by the FDA to treat Thrombocytopenia? | There are 8 Small molecule therapy drugs that are approved to treat Thrombocytopenia which are as follows: Prednisone, Dexamethasone, Fostamatinib Disodium, Avatrombopag Maleate, Eltrombopag Olamine, Lusutrombopag, Argatroban, and Azacitidine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thrombocytopenia" OR LOWER(mesh_heading) = "thrombocytopenia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217623', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_217831', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_218039', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_218247', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_218455', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_218663', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_218871', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_219079', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_219287', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_219495', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_219703', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_219911', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_220119', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_220327', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_220535', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_220743', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_226314', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_226599', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_226884', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_227169', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_227454', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_227739', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_228024', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_228309', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_228594', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_228879', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_229164', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_229449', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_229734', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_230019', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_230304', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_230589', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_230874', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_231159', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_231444', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_231729', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_232014', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_232299', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848737', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848744', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848751', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848758', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848765', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848772', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848779', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848786', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848793', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848800', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848807', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848814', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848821', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848828', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848835', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848842', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848849', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848856', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848863', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848870', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848877', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848884', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848891', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848898', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848905', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848912', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848919', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_848926', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165025', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055938', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055940', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055942', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055944', 'drugName': 'Avatrombopag Maleate', 'tradeNames_list': "['Doptelet']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055947', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055952', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055957', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055962', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055967', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055972', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055977', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055982', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055987', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055992', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1055997', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056002', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056007', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056012', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056017', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056022', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056027', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056032', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056037', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056042', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056047', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056052', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056057', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056062', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056067', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056072', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056077', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056082', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056087', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}, {'UUID': 'DrugTargetsIndication121923_text_1056092', 'drugName': 'Eltrombopag Olamine', 'tradeNames_list': "['Promacta', 'Promacta kit']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000117400', 'approvedSymbol': 'MPL', 'approvedName': 'MPL proto-oncogene, thrombopoietin receptor', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.173 | Q16 | What Protein therapies have been approved by the FDA to treat hereditary angioedema? | There are no drug Protein therapies approved to treat hereditary angioedema. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hereditary angioedema" OR LOWER(mesh_heading) = "hereditary angioedema") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.39 | Q16 | What Protein therapies have been approved by the FDA to treat Eczema? | There are no drug Protein therapies approved to treat Eczema. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "eczema" OR LOWER(mesh_heading) = "eczema") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.719 | Q16 | What Small molecule therapies have been approved by the FDA to treat adrenal gland hyperfunction? | There are 2 Small molecule therapy drugs that are approved to treat adrenal gland hyperfunction which are as follows: Dexamethasone and Levoketoconazole. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adrenal gland hyperfunction" OR LOWER(mesh_heading) = "adrenal gland hyperfunction") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226364', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_226649', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_226934', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_227219', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_227504', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_227789', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_228074', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_228359', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_228644', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_228929', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_229214', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_229499', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_229784', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_230069', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_230354', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_230639', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_230924', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_231209', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_231494', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_231779', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_232064', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_232349', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094183', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148795', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094187', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148795', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094191', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148795', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094195', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148795', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094199', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148795', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094203', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148795', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094207', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000179142', 'approvedSymbol': 'CYP11B2', 'approvedName': 'cytochrome P450 family 11 subfamily B member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094211', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000179142', 'approvedSymbol': 'CYP11B2', 'approvedName': 'cytochrome P450 family 11 subfamily B member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094215', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000179142', 'approvedSymbol': 'CYP11B2', 'approvedName': 'cytochrome P450 family 11 subfamily B member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094219', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000179142', 'approvedSymbol': 'CYP11B2', 'approvedName': 'cytochrome P450 family 11 subfamily B member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094223', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000179142', 'approvedSymbol': 'CYP11B2', 'approvedName': 'cytochrome P450 family 11 subfamily B member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094227', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000179142', 'approvedSymbol': 'CYP11B2', 'approvedName': 'cytochrome P450 family 11 subfamily B member 2', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094231', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160882', 'approvedSymbol': 'CYP11B1', 'approvedName': 'cytochrome P450 family 11 subfamily B member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094235', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160882', 'approvedSymbol': 'CYP11B1', 'approvedName': 'cytochrome P450 family 11 subfamily B member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094239', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160882', 'approvedSymbol': 'CYP11B1', 'approvedName': 'cytochrome P450 family 11 subfamily B member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094243', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160882', 'approvedSymbol': 'CYP11B1', 'approvedName': 'cytochrome P450 family 11 subfamily B member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094247', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160882', 'approvedSymbol': 'CYP11B1', 'approvedName': 'cytochrome P450 family 11 subfamily B member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094251', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160882', 'approvedSymbol': 'CYP11B1', 'approvedName': 'cytochrome P450 family 11 subfamily B member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094255', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140459', 'approvedSymbol': 'CYP11A1', 'approvedName': 'cytochrome P450 family 11 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094259', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140459', 'approvedSymbol': 'CYP11A1', 'approvedName': 'cytochrome P450 family 11 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094263', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140459', 'approvedSymbol': 'CYP11A1', 'approvedName': 'cytochrome P450 family 11 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094267', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140459', 'approvedSymbol': 'CYP11A1', 'approvedName': 'cytochrome P450 family 11 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094271', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140459', 'approvedSymbol': 'CYP11A1', 'approvedName': 'cytochrome P450 family 11 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}, {'UUID': 'DrugTargetsIndication121923_text_1094275', 'drugName': 'Levoketoconazole', 'tradeNames_list': "['Extina', 'Ketosidin', 'Ketozole', 'Nizoral', 'Nizoral A-D', 'PanfungolRecorlev', 'Xolegel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000140459', 'approvedSymbol': 'CYP11A1', 'approvedName': 'cytochrome P450 family 11 subfamily A member 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adrenocortical Hyperfunction', 'efo_term': 'adrenal gland hyperfunction'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.91 | Q16 | What Protein therapies have been approved by the FDA to treat amyotrophic lateral sclerosis? | There are no drug Protein therapies approved to treat amyotrophic lateral sclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "amyotrophic lateral sclerosis" OR LOWER(mesh_heading) = "amyotrophic lateral sclerosis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1703 | Q16 | What Small molecule therapies have been approved by the FDA to treat toothache? | There are 4 Small molecule therapy drugs that are approved to treat toothache which are as follows: Acetaminophen, Aspirin, Naproxen, and Ibuprofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "toothache" OR LOWER(mesh_heading) = "toothache") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828741', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_828846', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_828951', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829056', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829161', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829266', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829371', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829476', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829581', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829686', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829791', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_829896', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830001', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830106', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830211', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830316', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830421', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830526', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830631', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830736', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830841', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_830946', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831051', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831156', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831261', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831366', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831471', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831576', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831681', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831786', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831891', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_831996', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_832101', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_832206', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_832311', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_832416', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_832521', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_832626', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_832731', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_832836', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_833655', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_833812', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_833969', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_834126', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_834283', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_834440', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_834597', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_834754', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_834911', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_835068', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_835225', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_835382', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_835539', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_835696', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_835853', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_836010', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838344', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838385', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838426', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838467', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838508', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838549', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838590', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838631', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838672', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838713', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838754', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838795', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838836', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838877', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838918', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_838959', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839000', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839041', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839082', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839123', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839164', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839205', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839246', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839287', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839328', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839369', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839410', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839451', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839492', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839533', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839574', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839615', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839656', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839697', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839777', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839856', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_839935', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_840014', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_840093', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_840172', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_840251', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_840330', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_840409', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}, {'UUID': 'DrugTargetsIndication121923_text_840488', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.883 | Q16 | What Small molecule therapies have been approved by the FDA to treat cerebral infarction? | There are no drug Small molecule therapies approved to treat cerebral infarction. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cerebral infarction" OR LOWER(mesh_heading) = "cerebral infarction") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1184 | Q16 | What Small molecule therapies have been approved by the FDA to treat idiopathic pulmonary fibrosis? | There are 2 Small molecule therapy drugs that are approved to treat idiopathic pulmonary fibrosis which are as follows: Nintedanib Esylate and Nintedanib. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "idiopathic pulmonary fibrosis" OR LOWER(mesh_heading) = "idiopathic pulmonary fibrosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_678468', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678470', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678472', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678474', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678476', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678478', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678480', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678482', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678484', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678486', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678488', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678490', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678492', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678494', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678496', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678498', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678500', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678502', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678504', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678506', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678508', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678510', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678512', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678514', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678516', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678518', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678520', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678522', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678524', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678526', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678528', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678530', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678532', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678534', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678536', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678538', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678540', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678542', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678544', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678546', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678548', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678550', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678552', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678554', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678556', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678558', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678560', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678562', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678564', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678566', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678568', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678570', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678572', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678574', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678576', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678578', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678580', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678582', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678584', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678586', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678588', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678590', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678592', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678594', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678596', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678598', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678600', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678602', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678604', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678606', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678608', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678610', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678612', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678614', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678616', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678618', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678620', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678622', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678624', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678626', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678628', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678630', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678632', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678634', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678636', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678638', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678640', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678642', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678644', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678646', 'drugName': 'Nintedanib Esylate', 'tradeNames_list': "['Ofev']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678693', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678740', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678787', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678834', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678881', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678928', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_678975', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_679022', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_679069', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_679116', 'drugName': 'Nintedanib', 'tradeNames_list': "['Ofev', 'Vargatef']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Idiopathic Pulmonary Fibrosis', 'efo_term': 'idiopathic pulmonary fibrosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1102 | Q16 | What Small molecule therapies have been approved by the FDA to treat gastrointestinal stromal tumor? | There are 2 Small molecule therapy drugs that are approved to treat gastrointestinal stromal tumor which are as follows: Ripretinib and Avapritinib. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gastrointestinal stromal tumor" OR LOWER(mesh_heading) = "gastrointestinal stromal tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_933986', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_933988', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_933990', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_933992', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_933994', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_933996', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_933998', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934000', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934002', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934004', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934006', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934008', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934010', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934012', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934014', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934016', 'drugName': 'Ripretinib', 'tradeNames_list': "['Qinlock']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934022', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934028', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934034', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934040', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934046', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934052', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934058', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934064', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934070', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934076', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934082', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934088', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934094', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934100', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934106', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934112', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934118', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934124', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934130', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934136', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934142', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934148', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934154', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934160', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934166', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934172', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934178', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934184', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934190', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934196', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934202', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934208', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934214', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934220', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934226', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934232', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934238', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934244', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934250', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934256', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934262', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}, {'UUID': 'DrugTargetsIndication121923_text_934268', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1441 | Q16 | What Small molecule therapies have been approved by the FDA to treat pancreatic neuroendocrine tumor? | There are 2 Small molecule therapy drugs that are approved to treat pancreatic neuroendocrine tumor which are as follows: Everolimus and Belzutifan. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pancreatic neuroendocrine tumor" OR LOWER(mesh_heading) = "pancreatic neuroendocrine tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084963', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085098', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085233', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085368', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085503', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085638', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085773', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085908', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086043', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086178', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086313', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086448', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086583', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086718', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086853', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086988', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087123', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087258', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087393', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087528', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087663', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087798', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087933', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088068', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088203', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088338', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088473', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088608', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088743', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088878', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089013', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089148', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089283', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089418', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089553', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089688', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089823', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089958', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090093', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090228', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090363', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090498', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090633', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1192113', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116016', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1192121', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116016', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1722 | Q16 | What Small molecule therapies have been approved by the FDA to treat unspecified peripheral T-cell lymphoma? | There are 2 Small molecule therapy drugs that are approved to treat unspecified peripheral T-cell lymphoma which are as follows: Pralatrexate and Belinostat. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "unspecified peripheral t-cell lymphoma" OR LOWER(mesh_heading) = "unspecified peripheral t-cell lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072437', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072456', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072475', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072494', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072513', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1072532', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079813', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116478', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079849', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116478', 'approvedSymbol': 'HDAC1', 'approvedName': 'histone deacetylase 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079885', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171720', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079921', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171720', 'approvedSymbol': 'HDAC3', 'approvedName': 'histone deacetylase 3', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079957', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000094631', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1079993', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000094631', 'approvedSymbol': 'HDAC6', 'approvedName': 'histone deacetylase 6', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080029', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196591', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080065', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196591', 'approvedSymbol': 'HDAC2', 'approvedName': 'histone deacetylase 2', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080101', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108840', 'approvedSymbol': 'HDAC5', 'approvedName': 'histone deacetylase 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080137', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108840', 'approvedSymbol': 'HDAC5', 'approvedName': 'histone deacetylase 5', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080173', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000061273', 'approvedSymbol': 'HDAC7', 'approvedName': 'histone deacetylase 7', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080209', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000061273', 'approvedSymbol': 'HDAC7', 'approvedName': 'histone deacetylase 7', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080245', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000147099', 'approvedSymbol': 'HDAC8', 'approvedName': 'histone deacetylase 8', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080281', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000147099', 'approvedSymbol': 'HDAC8', 'approvedName': 'histone deacetylase 8', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080317', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163517', 'approvedSymbol': 'HDAC11', 'approvedName': 'histone deacetylase 11', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080353', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163517', 'approvedSymbol': 'HDAC11', 'approvedName': 'histone deacetylase 11', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080389', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068024', 'approvedSymbol': 'HDAC4', 'approvedName': 'histone deacetylase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080425', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068024', 'approvedSymbol': 'HDAC4', 'approvedName': 'histone deacetylase 4', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080461', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000048052', 'approvedSymbol': 'HDAC9', 'approvedName': 'histone deacetylase 9', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080497', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000048052', 'approvedSymbol': 'HDAC9', 'approvedName': 'histone deacetylase 9', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080533', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100429', 'approvedSymbol': 'HDAC10', 'approvedName': 'histone deacetylase 10', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_1080569', 'drugName': 'Belinostat', 'tradeNames_list': "['Beleodaq']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100429', 'approvedSymbol': 'HDAC10', 'approvedName': 'histone deacetylase 10', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, T-Cell, Peripheral', 'efo_term': 'unspecified peripheral T-cell lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.503 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hyperphosphatemia? | There are no drug Small molecule therapies approved to treat Hyperphosphatemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperphosphatemia" OR LOWER(mesh_heading) = "hyperphosphatemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.341 | Q16 | What Small molecule therapies have been approved by the FDA to treat Anti-neutrophil cytoplasmic antibody-associated vasculitis? | Avacopan is the only Small molecule therapy approved by the FDA to treat Anti-neutrophil cytoplasmic antibody-associated vasculitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anti-neutrophil cytoplasmic antibody-associated vasculitis" OR LOWER(mesh_heading) = "anti-neutrophil cytoplasmic antibody-associated vasculitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191848', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'anti-neutrophil antibody associated vasculitis'}, {'UUID': 'DrugTargetsIndication121923_text_1191851', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'Anti-neutrophil cytoplasmic antibody-associated vasculitis'}, {'UUID': 'DrugTargetsIndication121923_text_1191856', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'anti-neutrophil antibody associated vasculitis'}, {'UUID': 'DrugTargetsIndication121923_text_1191859', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'Anti-neutrophil cytoplasmic antibody-associated vasculitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.29 | Q16 | What Protein therapies have been approved by the FDA to treat Burkitts lymphoma? | There are no drug Protein therapies approved to treat Burkitts lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "burkitts lymphoma" OR LOWER(mesh_heading) = "burkitts lymphoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1459 | Q16 | What Small molecule therapies have been approved by the FDA to treat periarthritis? | There are no drug Small molecule therapies approved to treat periarthritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "periarthritis" OR LOWER(mesh_heading) = "periarthritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1601 | Q16 | What Small molecule therapies have been approved by the FDA to treat schizoaffective disorder? | There are 6 Small molecule therapy drugs that are approved to treat schizoaffective disorder which are as follows: Risperidone, Brexpiprazole, Clozapine, Aripiprazole, Paliperidone Palmitate, and Lurasidone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "schizoaffective disorder" OR LOWER(mesh_heading) = "schizoaffective disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149491', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149524', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149557', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149590', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149623', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149656', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149689', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149722', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149755', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149788', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149821', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149854', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149887', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149920', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149953', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_149986', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150019', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150052', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000147246', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150085', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150118', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150151', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150184', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150217', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150250', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150283', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150316', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150349', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150382', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150415', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150448', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150481', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150514', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150547', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150580', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150613', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150646', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150679', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150712', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150745', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150778', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150811', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150844', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150877', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150910', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150943', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_150976', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151009', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151042', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151075', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151108', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151141', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151174', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151207', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_151240', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155763', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155777', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155791', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155805', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155819', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155833', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155847', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155861', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155875', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155889', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155903', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155917', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155931', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155945', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155959', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155973', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_155987', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156001', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156015', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156029', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156043', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156057', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156071', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156085', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156099', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156113', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156127', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156141', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156155', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156169', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156183', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156197', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156211', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156225', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156239', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156253', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156267', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156281', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156295', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156309', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156323', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156337', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156351', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156365', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156379', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}, {'UUID': 'DrugTargetsIndication121923_text_156393', 'drugName': 'Brexpiprazole', 'tradeNames_list': "['Rexulti']", 'drugType': 'Small molecule', 'actionType': 'partial agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.953 | Q16 | What Small molecule therapies have been approved by the FDA to treat congenital heart disease? | There are no drug Small molecule therapies approved to treat congenital heart disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "congenital heart disease" OR LOWER(mesh_heading) = "congenital heart disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084208', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151617', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Defects, Congenital', 'efo_term': 'congenital heart disease'}, {'UUID': 'DrugTargetsIndication121923_text_1084236', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151617', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Defects, Congenital', 'efo_term': 'congenital heart disease'}, {'UUID': 'DrugTargetsIndication121923_text_1084264', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000136160', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Defects, Congenital', 'efo_term': 'congenital heart disease'}, {'UUID': 'DrugTargetsIndication121923_text_1084292', 'drugName': 'Bosentan', 'tradeNames_list': "['Tracleer']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000136160', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Defects, Congenital', 'efo_term': 'congenital heart disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.170 | Q16 | What Protein therapies have been approved by the FDA to treat hemorrhage? | Desmopressin Acetate is the only Protein therapy approved by the FDA to treat hemorrhage. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hemorrhage" OR LOWER(mesh_heading) = "hemorrhage") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_694397', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694408', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694419', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694430', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694441', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694452', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694463', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694474', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694485', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694496', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694507', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694518', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694529', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694540', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694551', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694562', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694573', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694584', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694595', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694606', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694617', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000126895', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694628', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694639', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694650', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694661', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694672', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694683', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694694', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694705', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694716', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694727', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694738', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694749', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694760', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694771', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694782', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694793', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694804', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694815', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694826', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694837', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694848', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000166148', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694859', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694870', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694881', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694892', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694903', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694914', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694925', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694936', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694947', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694958', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694969', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694980', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_694991', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_695002', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_695013', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_695024', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_695035', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_695046', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_695057', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_695068', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}, {'UUID': 'DrugTargetsIndication121923_text_695079', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000198049', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.